|
8
|
| 20 |
LRRK2
|
|
interacts (colocalizes) with
|
PRKN
|
|
|
16352719
|
Metabolic
Parkinson disease
|
|
62
|
| 1008 |
PRKN
|
|
decreases_activity of
|
neuron death
|
in substantia nigra
|
|
15576511
|
Parkinson disease 2, autosomal recessive juvenile
Parkinson disease
|
|
142
|
| 510 |
PRKN
|
|
is localized in
|
aggresome
|
if PARK2 is overexpressed
|
|
16805805
|
Parkinson disease
|
|
147
|
| 531 |
PRKN
|
|
interacts (colocalizes) with
|
PINK1
|
|
| 536 |
PRKN
|
NOT |
interacts (colocalizes) with
|
PINK1-p.H271Q
|
|
| 537 |
PRKN
|
NOT |
interacts (colocalizes) with
|
PINK1-p.G309D
|
|
| 538 |
PRKN
|
NOT |
interacts (colocalizes) with
|
PINK1-p.E417G
|
|
| 539 |
PRKN
|
|
decreases_ubiquitination/sumoylation of
|
PINK1
|
|
| 540 |
PRKN
|
NOT |
decreases_ubiquitination/sumoylation of
|
PINK1-p.H271Q
|
|
| 541 |
PRKN
|
NOT |
decreases_ubiquitination/sumoylation of
|
PINK1-p.G309D
|
|
| 542 |
PRKN
|
NOT |
decreases_ubiquitination/sumoylation of
|
PINK1-p.E417G
|
|
| 9363 |
PRKN
|
|
increases_quantity of
|
PINK1
|
by inhibiting its ubiquitin-mediated proteasomal degradation
|
| 9364 |
PRKN
|
NOT |
increases_quantity of
|
PINK1-p.H271Q
|
by inhibiting its ubiquitin-mediated proteasomal degradation
|
| 9365 |
PRKN
|
NOT |
increases_quantity of
|
PINK1-p.G309D
|
by inhibiting its ubiquitin-mediated proteasomal degradation
|
| 9366 |
PRKN
|
NOT |
increases_quantity of
|
PINK1-p.E417G
|
by inhibiting its ubiquitin-mediated proteasomal degradation
|
| 9367 |
PRKN
|
|
affects_activity of
|
proteasome-mediated ubiquitin-dependent protein catabolic process
|
|
|
19358826
|
Parkinson disease
|
|
148
|
| 548 |
PPD complex
|
|
increases_ubiquitination/sumoylation of
|
PRKN
|
|
| 558 |
PINK1
|
|
decreases_quantity of
|
PRKN
|
via ubiquitin-mediated proteasomal degradation
|
| 561 |
PINK1
|
|
increases_ubiquitination/sumoylation of
|
PRKN
|
|
| 563 |
PINK1-p.G309D
|
NOT |
decreases_quantity of
|
PRKN
|
via ubiquitin-mediated proteasomal degradation
|
| 565 |
PINK1-p.G309D
|
NOT |
increases_ubiquitination/sumoylation of
|
PRKN
|
|
|
19229105
|
Parkinson disease
|
|
152
|
| 571 |
PINK1
|
|
increases_transport of
|
PRKN
|
into mitochondria; by phosphorylation of PARK2
|
| 4052 |
PINK1
|
|
increases_phosphorylation of
|
PRKN
|
|
|
18957282
|
Parkinson disease
|
|
154
|
| 577 |
PRKN
|
|
is localized in
|
mitochondrion
|
in proliferating cells
|
| 578 |
PRKN
|
|
is localized in
|
cytoplasm
|
in differentiated or quiescent cells
|
| 590 |
PRKN
|
|
interacts (colocalizes) with
|
TFAM
|
in mitochondria
|
| 9354 |
PRKN
|
|
increases_activity of
|
TFAM
|
in mitochondria; thus increasing transcription activity in mitochondria
|
|
16449237
|
Parkinson disease
|
|
156
|
| 2626 |
PRKN
|
|
decreases_activity of
|
neuron death
|
if cell death has been induced by loss of PINK1
|
| 2653 |
PRKN
|
|
affects_activity of
|
PINK1
|
|
|
19279012
|
Parkinson disease
|
|
242
|
| 1014 |
MAPT-p.VLW
|
|
increases_expression of
|
PRKN
|
|
|
19057915
|
Parkinson disease
|
|
403
|
| 1731 |
PRKN
|
|
interacts (colocalizes) with
|
microtubule
|
|
| 1734 |
PRKN
|
|
interacts (colocalizes) with
|
TUBB
|
|
| 1736 |
PRKN
|
|
interacts (colocalizes) with
|
TUBA
|
|
| 1737 |
PRKN
|
|
interacts (colocalizes) with
|
Alpha/beta-tubulin complex
|
|
| 1743 |
PRKN
|
|
increases_ubiquitination/sumoylation of
|
TUBB
|
|
| 1744 |
PRKN
|
|
increases_ubiquitination/sumoylation of
|
TUBA
|
|
|
12716939
|
Parkinson disease
|
|
405
|
| 1738 |
PRKN
|
|
interacts (colocalizes) with
|
TUBB
|
|
| 1739 |
PRKN
|
|
interacts (colocalizes) with
|
TUBA
|
|
| 1741 |
PRKN
|
|
increases_ubiquitination/sumoylation of
|
TUBB
|
|
| 1742 |
PRKN
|
|
increases_ubiquitination/sumoylation of
|
TUBA
|
|
| 1759 |
PRKN
|
|
decreases_quantity of
|
TUBB
|
via ubiquitin-mediated proteasomal degradation
|
| 1760 |
PRKN
|
|
decreases_quantity of
|
TUBA
|
via ubiquitin-mediated proteasomal degradation
|
|
12716939
|
Parkinson disease
|
|
466
|
| 4007 |
PRKN
|
|
decreases_activity of
|
neuron death
|
|
|
19684592
|
Parkinson disease
|
|
499
|
| 2418 |
PRKN
|
|
is localized in
|
cytoplasm
|
|
| 2430 |
PRKN
|
|
is localized in
|
mitochondrion
|
|
| 2431 |
CCCP
|
|
increases_transport of
|
PRKN
|
into mitochondria
|
| 2432 |
mitochondrial depolarization
|
|
increases_transport of
|
PRKN
|
into mitochondria
|
| 2433 |
PRKN
|
|
increases_activity of
|
autophagy of mitochondrion
|
|
| 2434 |
PRKN
|
|
interacts (colocalizes) with
|
MAP1LC3A
|
after CCCP treatment
|
| 2556 |
mitochondrial depolarization
|
|
increases_transport of
|
PRKN
|
into mitochondria
|
| 9829 |
PRKN
|
|
decreases_activity of
|
abnormal mitochondrial physiology
|
by promoting autophagic degradation of mitochondria
|
|
19029340
|
Parkinson disease
|
|
500
|
| 2460 |
PRKN
|
|
affects_activity of
|
mitochondrial fragmentation involved in apoptotic process
|
which has been induced by PINK1 knockdown
|
| 2695 |
PRKN
|
|
affects_activity of
|
PINK1
|
|
|
17989306
|
Parkinson disease
|
|
517
|
| 2558 |
CCCP
|
|
increases_transport of
|
PRKN
|
into mitochondria
|
| 2559 |
FCCP
|
|
increases_transport of
|
PRKN
|
into mitochondria
|
| 2562 |
PINK1
|
|
increases_transport of
|
PRKN
|
into mitochondria; after CCCP treatment
|
| 2563 |
PARK7
|
NOT |
affects transport of
|
PRKN
|
into mitochondria; after CCCP treatment
|
| 2572 |
PINK1-p.W437X
|
NOT |
increases_transport of
|
PRKN
|
into mitochondria
|
| 2574 |
PINK1-p.L347P
|
NOT |
increases_transport of
|
PRKN
|
into mitochondria
|
| 2579 |
PRKN
|
|
interacts (colocalizes) with
|
PINK1
|
in mitochondria
|
| 2580 |
PRKN
|
NOT |
affects_ubiquitination/sumoylation of
|
PINK1
|
|
| 2582 |
PRKN
|
NOT |
affects_quantity of
|
PINK1
|
via ubiquitin-mediated proteasomal degradation
|
| 2584 |
PINK1
|
|
increases_transport of
|
PRKN
|
into mitochondria; if PINK1 is overexpressed
|
| 9824 |
PRKN
|
|
decreases_activity of
|
abnormal mitochondrial physiology
|
|
| 45616 |
PRKN
|
|
increases_activity of
|
autophagy of mitochondrion
|
together with Pink1
|
|
19966284
|
Parkinson disease
|
|
543
|
| 2744 |
CCCP
|
|
increases_transport of
|
PRKN
|
into mitochondria
|
| 2785 |
PRKN
|
|
increases_activity of
|
autophagy of mitochondrion
|
if Parkin is localized in mitochondria
|
| 2824 |
PINK1
|
|
affects transport of
|
PRKN
|
into mitochondria; after CCCP treatment
|
| 2850 |
PRKN
|
|
increases_ubiquitination/sumoylation of
|
VDAC1
|
after CCCP treatment
|
| 2857 |
VDAC1
|
|
affects transport of
|
PRKN
|
into mitochondria; after CCCP treatment
|
| 2859 |
TRAP1
|
NOT |
affects transport of
|
PRKN
|
into mitochondria; after CCCP treatment
|
|
20098416
|
Parkinson disease
|
|
558
|
| 2899 |
PRKN
|
|
affects_activity of
|
Parkinson disease 2, autosomal recessive juvenile
|
|
| 2900 |
PRKN
|
|
increases_quantity of
|
alpha-synuclein inclusion body
|
|
| 2999 |
PRKN
|
|
is localized in
|
alpha-synuclein inclusion body
|
of the substantia nigra
|
|
12000718
|
Dementia, Lewy body
Parkinson disease 2, autosomal recessive juvenile
Parkinson disease
|
|
560
|
| 2902 |
PARK7
|
NOT |
interacts (colocalizes) with
|
PRKN
|
|
| 2903 |
PARK7-p.L166P
|
|
interacts (colocalizes) with
|
PRKN
|
|
| 2909 |
PRKN
|
|
increases_ubiquitination/sumoylation of
|
PARK7-p.L166P
|
|
| 2911 |
PRKN
|
NOT |
increases_ubiquitination/sumoylation of
|
PARK7
|
|
| 2913 |
PRKN
|
NOT |
decreases_quantity of
|
PARK7-p.L166P
|
via ubiquitin-mediated proteasomal degradation
|
| 2915 |
PRKN
|
NOT |
decreases_quantity of
|
PARK7
|
via ubiquitin-mediated proteasomal degradation
|
| 2922 |
UBE2N
|
|
interacts (colocalizes) with
|
PRKN
|
|
| 2923 |
PRKN
|
|
interacts (colocalizes) with
|
UBE2G2
|
|
| 2928 |
PRKN
|
|
interacts (colocalizes) with
|
UBE2H
|
|
| 2929 |
PRKN
|
NOT |
interacts (colocalizes) with
|
UBE2D1
|
|
| 2939 |
PRKN
|
|
increases_activity of
|
protein K63-linked ubiquitination
|
of PARK7-L166P , together with UBC13-UEV1a complex
|
| 2940 |
PRKN
|
|
increases_ubiquitination/sumoylation of
|
PARK7-p.L166P
|
via K63-linked ubiquitin chains
|
| 2942 |
PRKN
|
|
is localized in
|
aggresome
|
after treatment with proteasome inhibitor MG132
|
| 2944 |
PRKN
|
|
increases_transport of
|
PARK7-p.L166P
|
into aggresome
|
| 2945 |
PRKN
|
NOT |
increases_transport of
|
PARK7
|
into aggresome
|
|
17846173
|
Parkinson disease
|
|
566
|
| 2953 |
PRKN
|
NOT |
affects_quantity of
|
PARK7-p.L166P
|
|
| 2954 |
PRKN
|
|
increases_transport of
|
PARK7-p.L166P
|
into aggresome
|
|
17846173
|
Parkinson disease
|
|
710
|
| 3931 |
PRKN
|
|
interacts (colocalizes) with
|
CTNNB1
|
|
| 3933 |
PRKN
|
|
decreases_quantity of
|
CTNNB1
|
|
| 3950 |
PRKN
|
|
affects_activity of
|
canonical Wnt signaling pathway
|
|
| 3974 |
PRKN
|
|
decreases_quantity of
|
CTNNB1
|
|
|
19591802
|
Parkinson disease
|
|
715
|
| 3975 |
PRKN
|
|
decreases_quantity of
|
CTNNB1
|
in ventral midbrain dopaminergic neurons
|
| 3979 |
PRKN
|
NOT |
affects_expression of
|
CTNNB1
|
in ventral midbrain dopaminergic neurons
|
| 3985 |
PRKN
|
|
affects_activity of
|
canonical Wnt signaling pathway
|
in ventral midbrain dopaminergic neurons
|
| 3987 |
PRKN
|
|
decreases_quantity of
|
CTNNB1
|
in ventral midbrain dopaminergic neurons
|
| 3988 |
PRKN
|
|
decreases_activity of
|
neuron death
|
in ventral midbrain dopaminergic neurons
|
|
19591802
|
Parkinson disease
|
|
720
|
| 4058 |
PRKN
|
|
affects_activity of
|
LRRK2
|
|
|
19692353
|
Parkinson disease
|
|
721
|
| 4065 |
PRKN
|
|
decreases_activity of
|
neuron death
|
induced by LRRK2-p.G2019S mutant
|
| 4066 |
PRKN
|
|
decreases_activity of
|
LRRK2-p.G2019S
|
|
|
19741132
|
Parkinson disease
|
|
785
|
| 4397 |
PRKN
|
|
interacts (colocalizes) with
|
LIMK1
|
also in the presence of CHIP
|
| 4398 |
PRKN
|
|
interacts (colocalizes) with
|
LIMK2
|
|
| 4414 |
PRKN
|
|
interacts (colocalizes) with
|
FBXW7
|
|
| 4417 |
HSP70
|
|
interacts (colocalizes) with
|
PRKN
|
|
| 4426 |
PRKN
|
|
increases_ubiquitination/sumoylation of
|
LIMK1
|
in vitro or in BE(2)-M17 cells, but not in HEK293 cells
|
| 4431 |
PRKN
|
|
decreases_activity of
|
LIMK1
|
in a cell type-dependent manner
|
| 4443 |
PRKN
|
|
decreases_activity of
|
actin filament polymerization
|
through ubiquitination of LIMK1
|
| 4446 |
PRKN
|
|
increases_activity of
|
actin filament depolymerization
|
through ubiquitination of LIMK1
|
| 4455 |
LIMK1
|
NOT |
increases_phosphorylation of
|
PRKN
|
|
| 4456 |
Protein kinase A
|
|
increases_phosphorylation of
|
PRKN
|
|
| 4457 |
PRKN
|
|
increases_ubiquitination/sumoylation of
|
PRKN
|
|
| 4459 |
LIMK1
|
|
decreases_activity of
|
PRKN
|
|
| 4462 |
LIMK1
|
|
decreases_ubiquitination/sumoylation of
|
PRKN
|
|
|
17512523
|
Parkinson disease
|
|
823
|
| 4757 |
PRKN
|
|
interacts (colocalizes) with
|
UBE2L3
|
|
| 4758 |
PRKN
|
|
interacts (colocalizes) with
|
UBE2L6
|
|
| 4759 |
PRKN
|
NOT |
interacts (colocalizes) with
|
UBE2B
|
|
| 4760 |
PRKN
|
NOT |
interacts (colocalizes) with
|
CDC34
|
|
| 4761 |
PRKN
|
NOT |
interacts (colocalizes) with
|
UBE2D2
|
|
| 4762 |
PRKN
|
NOT |
interacts (colocalizes) with
|
UBE2D1
|
|
| 4763 |
PRKN
|
NOT |
interacts (colocalizes) with
|
UBE2D3
|
|
| 4764 |
PRKN
|
NOT |
interacts (colocalizes) with
|
UBE2E1
|
|
| 4765 |
PRKN
|
|
increases_activity of
|
protein ubiquitination
|
|
|
10888878
|
Parkinson disease 2, autosomal recessive juvenile
Parkinson disease
|
|
825
|
| 4774 |
PRKN
|
|
is localized in
|
alpha-synuclein inclusion body
|
in brainstem
|
| 4776 |
PRKN
|
|
interacts (colocalizes) with
|
UBE2L3
|
in brainstem
|
| 4779 |
PRKN
|
|
increases_ubiquitination/sumoylation of
|
SNCA
|
|
|
11431533
|
Parkinson disease
|
|
867
|
| 5210 |
GGEL
|
|
interacts (colocalizes) with
|
PRKN
|
in UPP (ubiquitin-immunopositive, insoluble protein particles)
|
|
15132984
|
Alzheimer disease
Huntington disease
|
|
874
|
| 5158 |
PRKN
|
NOT |
interacts (colocalizes) with
|
PSMD5
|
|
| 5160 |
PRKN
|
NOT |
interacts (colocalizes) with
|
Epsin
|
|
| 5161 |
PRKN
|
|
interacts (colocalizes) with
|
EPS15
|
|
|
16862145
|
Parkinson disease
|
|
876
|
| 5163 |
PRKN
|
|
interacts (colocalizes) with
|
EPS15
|
|
|
16862145
|
Parkinson disease
|
|
878
|
| 5169 |
PRKN
|
|
interacts (colocalizes) with
|
EPS15
|
|
| 5172 |
PRKN
|
|
affects_activity of
|
epidermal growth factor receptor signaling pathway
|
|
|
16862145
|
Parkinson disease
|
CIDeRplus